» Articles » PMID: 39851545

-Rearranged Enteric Tumors: Updates on Clinicopathologic and Molecular Genetics Features

Overview
Journal Cells
Publisher MDPI
Date 2025 Jan 24
PMID 39851545
Authors
Affiliations
Soon will be listed here.
Abstract

Recent advances in molecular genetics, particularly in identifying and characterizing genetic abnormalities within mesenchymal neoplasms, have led to a more comprehensive and evolving classification system. Modern technological developments in cytogenetics and next-generation sequencing have enabled the analysis of small clinical samples, expanded our understanding of tumor biology, and improved the diagnostic, prognostic, and predictive precision by identifying targeted genetic alterations, confirming the presence of fusion transcripts, and/or revealing the overexpression of specific genes and their targets. In this review, we focus specifically on the -rearranged enteric tumor, a recent clinicopathological entity that has emerged within the expanding classification of mesenchymal tumors. Herein, we aim to explore the histopathological features, molecular genetic characteristics, and clinical outcomes in these tumors. Due to their rarity and the extensive overlapping in their histopathological and molecular features with other neoplasms, continued research and systematic documentation of -rearranged enteric tumors is necessary to better understand their biological behavior, develop more accurate prognostic indicators, and establish optimal treatment strategies.

References
1.
Yang Q, Ciebiera M, Bariani M, Ali M, Elkafas H, Boyer T . Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2021; 43(4):678-719. PMC: 9277653. DOI: 10.1210/endrev/bnab039. View

2.
Chai J, Sugumar V, Alshanon A, Wong W, Fung S, Looi C . Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches. Cancers (Basel). 2021; 13(19). PMC: 8507559. DOI: 10.3390/cancers13194746. View

3.
Zhang R, Ma J, Avery J, Sambandam V, Nguyen T, Xu B . GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAF Colorectal Cancer. Front Oncol. 2020; 10:241. PMC: 7058788. DOI: 10.3389/fonc.2020.00241. View

4.
Duan G, Zhang C, Xu C, Xu C, Zhang L, Zhang Y . Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR‑34a/cyclin D1 axis. Int J Oncol. 2018; 54(1):17-28. PMC: 6254999. DOI: 10.3892/ijo.2018.4600. View

5.
Yeung M, Liu A, Wong S, Loong H, Shek T . GLI1-Altered Mesenchymal Tumor-Multiomic Characterization of a Case Series and Patient-Level Meta-analysis of One Hundred Sixty-Seven Cases for Risk Stratification. Mod Pathol. 2024; 38(1):100635. DOI: 10.1016/j.modpat.2024.100635. View